Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma

BACKGROUND: The FOLFIRINOX regimen is the standard first-line treatment for advanced pancreatic adenocarcinoma (aPDAC). However, because of its potential toxicity, predictive biomarkers could help clinical decision-making. METHODS: A cohort of 97 aPDAC patients treated with first-line FOLFIRINOX wer...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Aarnink, Anne, Richard, Corentin, Truntzer, Caroline, Vincent, Julie, Bengrine, Leila, Vienot, Angélique, Borg, Christophe, Ghiringhelli, Francois
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986639/
https://ncbi.nlm.nih.gov/pubmed/29876012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25424
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki